Rombocytosis, platelet activation, and plateletleukocyte aggregation described for IBD patients are

Rombocytosis, platelet activation, and plateletleukocyte aggregation described for IBD sufferers are also manifested in both the DSS and Tcell transfer models of colonic inflammation. These models might prove valuable for future research that address the underlying mechanisms and pathophysiological consequences of the platelet abnormalities and enhanced thrombus development that have been described in human IBD.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptAcknowledgmentsWe thank Dr. Robert Chervenak, Dr. Karen Stokes, Dr. Dmitry Ostanin, and Laura Gray (LSUHSC-Shreveport) and Renata Polanowska-Grabowska (University of Virginia) for their knowledge and valuable comments, and Deborah Chervenak (LSUHSC Investigation Core Facility) for her important assistance. Supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (P01 DK43785-20)
Quick CommunicationsMontmorillonite Poly-L-Lactide Microcomposites of Procainamide for controlled drug delivery: In vitro and In vivo evaluationB. D. KEVADIYA1, T. K. PATEL2, PARVATI B. PATEL2, SHALINI RAJKUMAR1, C. B. TRIPATHI2 AND H. C. BAJAJ*Discipline of Inorganic Materials and Catalysis, Central Salt and Marine Chemical compounds, Study Institute, Council of Scientific and Industrial Research (CSIR), Gijubhai Badheka Marg, Bhavnagar-364 002, 1Institute of Science, Nirma University, S. G. highway,Ahmedabad-382 481, 2Department of Pharmacology, Government Health-related College, Bhavnagar University, Jail road, Bhavnagar-364 002, India.Kevadiya, et al.: MMT/PLLA Microcomposites of Procainamide for Controlled Drug Delivery The analysis function reported within this paper is extension of our earlier findings associated with intercalation of procainamide hydrochloride, an antiarrythmia drug in interlayer gallery of Na+-clay (montmorillonite). The microcomposite particles ready from procainamide-montmorillonite hybrid and poly L-lactide were characterised by scanning electron microscope and atomic force microscopy evaluation. In vitro drug release study in simulated intestinal fluid showed controlled release pattern up to 72 h and significant reduction within the drug release in gastric environment. In vivo pharmacokinetics and biodistribution in rats showed that the plasma/tissue drug levels had been within therapeutic window as compared with cost-free drug. The data from toxicity biomarker estimations and clinical biochemistry/ haematological parameters showed considerable reduction in drug toxicity when formulated in montmorillonite/poly L-lactide as compared with free drug, which is of considerable worth in reaching improved therapy with lowered side effects.1438382-15-0 Formula Important words: Antiarrythmia, controlled release, microcomposites, procainamide, toxicity biomarkerLayered silicates are emerging as promising candidates for applications in biomedical study encompassing drug delivery[1-5], tissue engineering[6,7], protein adsorption [8-11] , gene reservoirs and delivery[12,13] and nanoclay composites on account of their ultra fine sizes are valuable in tissue engineering applications [14-16], biocompatibility and controlled release of drug[4,five,14-16].N-Methyl-L-valine site For delivery applications, the layered silicates are excellent model for higher level of controlled release of drug and biomolecules, strength and null toxicity[4-5,14-18].PMID:23715856 The goal of this study was to utilize montmorillonite/ Na+-clay (MMT) as carrier for controlled releases of procainamide hydrochloride (PA) and to achieve a delivery profile that would yield a higher bloo.